Vericel Corp (VCEL)

• Market cap: $2.79B
• 1 day: 2.82%
• 5 days: -1.50%
• 1 month: -1.33%
• 3 months: 21.32%
• 6 months: 26.51%
• Year to date: 61.98%
• 1 year: 65.98%
• 5 years: 226.21%
• 10 years: 2,048.29%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Employees: 314

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

368% more call options, than puts

Call options by funds: $4.67M | Put options by funds: $997K

19% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 27

14% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 88

2% more funds holding

Funds holding: 257 [Q2] → 262 (+5) [Q3]

1.35% less ownership

Funds ownership: 105.06% [Q2] → 103.71% (-1.35%) [Q3]

9% less capital invested

Capital invested by funds: $2.34B [Q2] → $2.13B (-$210M) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 0 (-2) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60 6% upside
• Avg. target: $63 12% upside
• High target: $67 19% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Truist Securities Samuel Brodovsky 87% 1-year accuracy 13 / 15 met price target	19% upside $67	Buy Maintained	18 Dec 2024
BTIG Ryan Zimmerman 63% 1-year accuracy 30 / 48 met price target	17% upside $66	Buy Maintained	26 Nov 2024
Canaccord Genuity Caitlin Cronin 58% 1-year accuracy 7 / 12 met price target	6% upside $60	Buy Maintained	19 Nov 2024
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target	6% upside $60	Buy Reiterated	8 Nov 2024